Summary

U.S. Drug Of Abuse Testing Services Market Growth & Trends

The U.S. drug of abuse testing services market size is anticipated to reach USD 1.29 billion by 2030, registering a CAGR of 4.65% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market growth is driven by several key factors, including rising substance abuse rates, stringent workplace safety regulations, and the growing need for compliance with federal and state mandates. Increasing adoption of pre-employment and random drug screening in industries like transportation, healthcare, and manufacturing is likely to propel the demand.

The ongoing opioid crisis has intensified the need for comprehensive drug testing services, with both government agencies and private organizations investing in expanded testing capabilities to address this public health emergency. In addition, the rise in recreational drug use, including cannabis, in several states, has increased the demand for testing solutions that can differentiate between legal and illegal substances, contributing to the market expansion.

The regulatory environment in the U.S. continues to support market growth, as stringent workplace drug testing policies and guidelines from organizations like SAMHSA and DOT ensure the widespread adoption of testing services. Employers across industries such as transportation, healthcare, and manufacturing are increasingly implementing drug testing protocols to comply with these regulations and ensure workplace safety. The introduction of new testing technologies, such as rapid testing kits, saliva-based tests, and mobile testing units, has further fueled market growth by providing more convenient, cost-effective, and accurate solutions for drug detection.

Technological innovation is also a major driver of market growth, as advancements in testing technologies are making drug testing more efficient, accurate, and accessible. The introduction of multiplex testing platforms and automation in laboratories has improved turnaround times and reduced human error, while artificial intelligence and machine learning applications offer enhanced data analysis capabilities for better decision-making. These innovations are attracting new market players and investors, fostering competition and further propelling market expansion. In addition, increasing acceptance of at-home drug testing kits and mobile testing services has broadened the market, appealing to both individuals and organizations seeking convenient, non-invasive solutions.

Some key players in the market are Omega Laboratories, Inc., Clinical Reference Laboratory (CRL), Inc., Millennium Health, LLC, Cordant Health Solutions, Psychemedics Corporation, Abbott, DrugScan, Quest Diagnostics, Legacy Medical Services, and Laboratory Corporation of America Holdings. Key players are focusing on new product launches to increase their market presence. For instance, In October 2023, Psychemedics Corporation revealed its Advanced 5- Panel Drug Screen, a U.S. FDA-cleared test designed to identify fentanyl. This new panel addresses the increasing prevalence of fentanyl and includes tests for PCP, cocaine, amphetamines, and opioids. It significantly improves accuracy, being 25 times more effective at detecting opioids, 23 times more for cocaine, and 13 times more for amphetamines compared to conventional tests.

U.S. Drug Of Abuse Testing Services Market Report Highlights

• Based on drug, the cannabis/marijuana accounted for 57.32% revenue share in 2024. With legalization of cannabis in various states across the U.S, the illicit consumption of cannabis has been increasing across age groups. This is the major factor for the segment dominance within the U.S.

• The growing prevalence of substance abuse, particularly opioids and synthetic drugs, has driven the need for expanded testing services in the U.S. This trend is further supported by rising public health concerns and efforts to combat the opioid crisis through early detection and intervention

• Stringent regulatory mandates such as the Drug-Free Workplace Act and Department of Transportation (DOT) regulations have resulted in routine drug testing for safety-sensitive positions, contributing to high demand for testing services

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Drug
1.2.2. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Drug outlook
2.3. Competitive Insights
Chapter 3. U.S. Drug of Abuse Testing Services Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rising prevalence of substance use in the workplace
3.2.1.2. Stringent laws mandating alcohol and drug testing in the workplace
3.2.1.3. Rapid growth in illicit substance consumption
3.2.2. Market restraint analysis
3.2.2.1. Changing legal environment and societal norms
3.2.3. Market opportunity analysis
3.2.3.1. Technological advancements in drug testing for workplace
3.2.4. Market risk analysis
3.2.4.1. Potential for legal and regulatory changes
3.3. U.S. Drug of Abuse Testing Services Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. U.S. Drug of Abuse Testing Services Market: Drug Estimates & Trend Analysis
4.1. Drug Market Share, 2024 & 2030
4.2. Segment Dashboard
4.3. U.S. U.S. Drug of Abuse Testing Services Market by Drug Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. Alcohol
4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.2. Cannabis/Marijuana
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3. Cocaine
4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.4. Opioids
4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.5. Amphetamine & Methamphetamine
4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.6. LSD
4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.7. Others
4.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Competitive Landscape
5.1. Recent Developments & Impact Analysis, By Key Market Participants
5.2. Company/Competition Categorization
5.3. Vendor Landscape
5.3.1. Key company market share analysis, 2024
5.3.2. Quest Diagnostics
5.3.2.1. Company overview
5.3.2.2. Financial performance
5.3.2.3. Product benchmarking
5.3.2.4. Strategic initiatives
5.3.3. Abbott
5.3.3.1. Company overview
5.3.3.2. Financial performance
5.3.3.3. Product benchmarking
5.3.3.4. Strategic initiatives
5.3.4. Clinical Reference Laboratory (CRL), Inc.
5.3.4.1. Company overview
5.3.4.2. Financial performance
5.3.4.3. Product benchmarking
5.3.4.4. Strategic initiatives
5.3.5. Laboratory Corporation of America Holdings
5.3.5.1. Company overview
5.3.5.2. Financial performance
5.3.5.3. Product benchmarking
5.3.5.4. Strategic initiatives
5.3.6. Cordant Health Solutions
5.3.6.1. Company overview
5.3.6.2. Financial performance
5.3.6.3. Product benchmarking
5.3.6.4. Strategic initiatives
5.3.7. Legacy Medical Services
5.3.7.1. Company overview
5.3.7.2. Financial performance
5.3.7.3. Product benchmarking
5.3.7.4. Strategic initiatives
5.3.8. DrugScan
5.3.8.1. Company overview
5.3.8.2. Financial performance
5.3.8.3. Product benchmarking
5.3.8.4. Strategic initiatives
5.3.9. Omega Laboratories, Inc.
5.3.9.1. Company overview
5.3.9.2. Financial performance
5.3.9.3. Product benchmarking
5.3.9.4. Strategic initiatives
5.3.10. Psychemedics Corporation
5.3.10.1. Company overview
5.3.10.2. Financial performance
5.3.10.3. Product benchmarking
5.3.10.4. Strategic initiatives
5.3.11. Millennium Health, LLC
5.3.11.1. Company overview
5.3.11.2. Financial performance
5.3.11.3. Product benchmarking
5.3.11.4. Strategic initiatives